SlidesetViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025Abstract #22 Chronic HDV Co-Infection Is Characterized by a More Elevated Production of All Three HBsAg Isoforms Compared to HBV Mono-Infection, That Parallels HDV Replicative and Cytolytic Activity - Stefano D'AnnaView Slideset
VSValentina SvicherPhDSlidesetViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025Update Novel Biomarkers and Compounds in HBV/HDV - Valentina SvicherView Slideset
SlidesetViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025Abstract #21 Viral Strain Networks Tracing Human or Environment-Linked Hepatitis E Virus Dispersion in Europe: HEV Molecular Signatures - Evelyne SchvoererView Slideset
FGFederico GarcíaPharmD, PhDSlidesetViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025Abstract #20 Boosting HDV Testing in Spain through the Delta Double Reflex Strategy - Federico GarcíaView Slideset
SlidesetViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025Abstract #19 Despite a Substantial Burden of HDV Infection, Gaps in HDV Screening Still Persists Across Europe: An Urgent Need to Strengthen Diagnostic Strategies at a Pan-European Level - Ilaria GrossiView Slideset
SlidesetViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025HCV Micro-Elimination Approaches: IV Drug Users – Spilios ManolakopoulosView Slideset
PKPavel KhaykinMDSlidesetViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025HCV Elimination: Why Do We Still Have Gaps and How Do We Close These Gaps? - Pavel KhaykinView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #17 Clonal Analysis of Near Full-Length Proviral HIV-1 Genome Enables Differentiation of APOBEC- and Drug-Resistant Populations in Highly Treatment Experienced People Living with HIV - Martin DäumerView Slideset
FGFederico GarcíaPharmD, PhDSlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #16 APOBEC-Associated Mutations in HIV Drug Resistance: Challenges in Interpretation Using Next-Generation Sequencing - Federico GarcíaView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #15 Virologic Failure and Resistance Emergence During Treatment with B/F/TAF or DTG/3TC in PWH Without Prior Resistance Mutations: A Real-World Study - Thomas DrumelView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #14 Three-Years Outcome After Genotyping-Guided Switch in HIV Multi-Drug Resistant Patients in Cameroon: Evidence-Based Strategies for Achieving Epidemic Control in Low-and Middle-Income Countries - Ezechiel Ngoufack Jagni SemengueView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #13 Estimating the Genetic Barrier for Resistance to Integrase Inhibitors for the Most Frequently Circulating HIV-1 Subtypes - Mafalda N.S. MirandaView Slideset
